Seeking Alpha

Sanofi (SNY) presented an overview today of Phase II and Phase III clinical trials for its...

Sanofi (SNY) presented an overview today of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine, QIV. Three clinical trials have been conducted to evaluate the safety and the immune response to the vaccine, which SNY says is the next evolutionary stage in protecting against influenza B, a significant cause of influenza illness and associated complications across all ages, and especially children.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|